Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20121018210644im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Acute and sub-chronic administration of olanzapine has shown a favourable effect on the sleep disturbances in previously medicated schizophrenia patients with predominantly negative symptoms. The present study will be carried out to clarify the effect of olanzapine on polysomnographic profiles of schizophrenia patients in an acute phase of illness after controlling for the drug effects.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia Sleep |
Drug: Olanzapine |
Phase 4 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
- Sleep EEG [ Time Frame: 06 weeks ] [ Designated as safety issue: No ]Changes in Sleep EEG parameters like Total sleep time, total sleep period, sleep efficiency, sleep latency, stage shifts, stage 1 shifts, stage 1 parameters, stage 2 parameters, stage 3 parameters, stage 4 parameters, rapid eye movement (REM) parameters.
- Psychopathology [ Time Frame: 06 weeks ] [ Designated as safety issue: No ]Changes in psychopathological scores as measured by Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS).
Enrollment: | 25 |
Study Start Date: | August 2007 |
Study Completion Date: | April 2009 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Schizophrenia patients
The study population of 25 schizophrenia patients constituted the active arm of the study.
|
Drug: Olanzapine
06 weeks treatment with Olanzapine in a flexible dosage schedule.
|
Detailed Description:
Twenty schizophrenia patients (11 drug naïve and 9 drug free) will be studied over a period of six weeks of olanzapine treatment. Patients will be assessed at the baseline on BPRS, PANSS, CDSS and UKU side effect rating scales and a baseline 40 channels polysomnography will be done. After the initial assessment, patients will put on olanzapine treatment, in flexible dosages based on clinical response, for a period of six weeks when a final assessment on clinical rating scales and polysomnography will be done. The sleep data will be scored manually for staging based on Rechtschaffen and Kales criteria.
![](https://webarchive.library.unt.edu/web/20121018210644im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male patients fulfilling International Classification of Diseases-10 Diagnostic Criteria for Research for schizophrenia
- Aged 18-50 Yrs
- Drug naïve or drug free (not receiving any psychotropic medication for the past 4 months)
- Consenting
Exclusion Criteria:
- Any comorbid psychiatric illness
- Significant medical or neurological illness
- History of significant head injury, epilepsy
- Substance use in the past 4 months excluding nicotine and caffeine
- Presence of a primary sleep disorder
![](https://webarchive.library.unt.edu/web/20121018210644im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
India | |
Central Institute of Psychiatry | |
Ranchi, Jharkhand, India, 834006 |
Principal Investigator: | Mohammad Zia Ul Haq Katshu, DPM | Central Institute of Psychiatry |
![](https://webarchive.library.unt.edu/web/20121018210644im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | S Haque Nizamie, Central Institute of Psychiatry |
ClinicalTrials.gov Identifier: | NCT01149577 History of Changes |
Other Study ID Numbers: | SCHOLZ0003 |
Study First Received: | June 18, 2010 |
Last Updated: | June 22, 2010 |
Health Authority: | India: Institutional Review Board |
Keywords provided by Central Institute of Psychiatry, Ranchi, India:
Olanzapine Schizophrenia Polysomnography Slow wave sleep |
Additional relevant MeSH terms:
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Olanzapine Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents |
ClinicalTrials.gov processed this record on October 17, 2012